Rallybio Past Earnings Performance
Past criteria checks 0/6
Rallybio's earnings have been declining at an average annual rate of -22.7%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 114.9% per year.
Key information
-22.7%
Earnings growth rate
32.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 114.9% |
| Return on equity | -94.6% |
| Net Margin | -11,199.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully
Aug 28
Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?
Jan 04Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?
Sep 19Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation
May 15We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth
Jan 30Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation
Oct 31Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation
Jul 07Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans
Mar 16Revenue & Expenses Breakdown
How Rallybio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1 | -67 | 19 | 54 |
| 30 Jun 24 | 0 | -74 | 21 | 54 |
| 31 Mar 24 | 0 | -76 | 24 | 53 |
| 31 Dec 23 | 0 | -75 | 25 | 54 |
| 30 Sep 23 | 0 | -71 | 26 | 11 |
| 30 Jun 23 | 0 | -71 | 27 | 23 |
| 31 Mar 23 | 0 | -69 | 28 | 44 |
| 31 Dec 22 | 0 | -67 | 27 | 41 |
| 30 Sep 22 | 0 | -63 | 27 | 36 |
| 30 Jun 22 | 0 | -55 | 25 | 29 |
| 31 Mar 22 | 0 | -48 | 22 | 26 |
| 31 Dec 21 | 0 | -47 | 19 | 27 |
| 30 Sep 21 | 0 | -45 | 15 | 28 |
| 30 Jun 21 | 0 | -42 | 12 | 28 |
| 31 Mar 21 | 0 | -36 | 10 | 25 |
| 31 Dec 20 | 0 | -26 | 8 | 18 |
Quality Earnings: RLYB is currently unprofitable.
Growing Profit Margin: RLYB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RLYB is unprofitable, and losses have increased over the past 5 years at a rate of 22.7% per year.
Accelerating Growth: Unable to compare RLYB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RLYB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: RLYB has a negative Return on Equity (-94.57%), as it is currently unprofitable.